UY33533A - siRNA DIRIGIDO AL VEGFA Y A MÉTODOS DE TRATAMIENTO IN VIVO - Google Patents

siRNA DIRIGIDO AL VEGFA Y A MÉTODOS DE TRATAMIENTO IN VIVO

Info

Publication number
UY33533A
UY33533A UY0001033533A UY33533A UY33533A UY 33533 A UY33533 A UY 33533A UY 0001033533 A UY0001033533 A UY 0001033533A UY 33533 A UY33533 A UY 33533A UY 33533 A UY33533 A UY 33533A
Authority
UY
Uruguay
Prior art keywords
vegfa
syrna
aimed
treatment methods
vivo treatment
Prior art date
Application number
UY0001033533A
Other languages
English (en)
Inventor
Smith Anja
Reynolds Angela
Jon E Chatterton
Zhang Xinyu
Original Assignee
Alcon Res Ltd
Dharmacon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45527345&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY33533(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Res Ltd, Dharmacon Inc filed Critical Alcon Res Ltd
Publication of UY33533A publication Critical patent/UY33533A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)

Abstract

El factor de crecimiento endotelial vascular A(VEGFA) es una señal química producida por células que estimulan el crecimiento de nuevos vasos sanguíneos, y la sobreexpresión del VEGFA puede llevar a condiciones fisiológicas no deseadas. Mediante la identificación del nuevo siRNA y modificaciones que mejoran la habilidad de silenciar dicho siRNA in vivo, se han inventado composiciones y métodos terapéuticos para tratar los problemas asociados con dicha sobreexpresión.
UY0001033533A 2010-07-28 2011-07-27 siRNA DIRIGIDO AL VEGFA Y A MÉTODOS DE TRATAMIENTO IN VIVO UY33533A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36838510P 2010-07-28 2010-07-28

Publications (1)

Publication Number Publication Date
UY33533A true UY33533A (es) 2012-02-29

Family

ID=45527345

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033533A UY33533A (es) 2010-07-28 2011-07-27 siRNA DIRIGIDO AL VEGFA Y A MÉTODOS DE TRATAMIENTO IN VIVO

Country Status (17)

Country Link
US (2) US8546349B2 (es)
EP (1) EP2598639A4 (es)
JP (1) JP2013539456A (es)
KR (1) KR20130095737A (es)
CN (1) CN103068981A (es)
AR (1) AR082411A1 (es)
AU (1) AU2011282902B2 (es)
BR (1) BR112013001918A2 (es)
CA (1) CA2804847A1 (es)
CL (1) CL2013000237A1 (es)
MX (1) MX2013000986A (es)
PH (1) PH12013500187A1 (es)
RU (1) RU2013102545A (es)
TW (1) TW201219041A (es)
UY (1) UY33533A (es)
WO (1) WO2012015775A2 (es)
ZA (1) ZA201300531B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150103280A (ko) * 2013-01-08 2015-09-09 베니텍 바이오파마 리미티드 연령-관련 황반 변성 치료
EP2986599A1 (en) 2013-04-17 2016-02-24 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
TWI496595B (zh) * 2013-06-07 2015-08-21 Univ Nat Taiwan Ocean 製備魚類核醣核酸試劑之方法
KR102298599B1 (ko) * 2014-04-29 2021-09-03 마이크로소프트 테크놀로지 라이센싱, 엘엘씨 샘플 적응 오프셋 필터링에 대한 인코더측 결정
JP2018515142A (ja) * 2015-05-15 2018-06-14 ダーマコン，インコーポレイテッド． Ｃａｓ９介在遺伝子編集用の合成シングルガイドｒｎａ
WO2017173327A1 (en) * 2016-03-31 2017-10-05 The Schepens Eye Research Institute, Inc. Endomucin inhibitor as an anti-angiogenic agent
GB201802404D0 (en) * 2018-02-14 2018-03-28 Univ Malta Methods
WO2019195936A1 (en) * 2018-04-10 2019-10-17 Ilkow Carolina Solange Microrna-based compositions and methods used in disease treatment
JP7698252B2 (ja) * 2019-09-06 2025-06-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 治療薬の核酸媒介性送達
IL295445A (en) * 2020-02-10 2022-10-01 Alnylam Pharmaceuticals Inc Preparations and methods for silencing vegf-a expression
AU2024353921A1 (en) * 2023-09-27 2026-04-16 Neuro3 Therapeutics (Suzhou) Ltd. Novel sirna constructs, therapeutics, and modifications

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306829B1 (en) 1995-12-08 2001-10-23 Hybridon, Inc. Modified VEGF oligonucleotides for treatment of skin disorders
US5731294A (en) 1993-07-27 1998-03-24 Hybridon, Inc. Inhibition of neovasularization using VEGF-specific oligonucleotides
US6410322B1 (en) 1993-07-27 2002-06-25 Hybridon Inc Antisense oligonucleotide inhibition of vascular endothelial growth factor expression
US5641756A (en) 1993-07-27 1997-06-24 Hybridon, Inc. Modified VEGF oligonucleotides
US6150092A (en) 1994-06-27 2000-11-21 Taogosei Company, Ltd. Antisense nucleic acid compound targeted to VEGF
US5830879A (en) 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor
WO2002096927A2 (en) 2001-05-29 2002-12-05 Ribozyme Pharmaceuticals, Incorporated Ribozyme based treatment of female reproductive diseases
JP2000501941A (ja) 1995-12-08 2000-02-22 ハイブリドン・インコーポレイテッド 修飾ｖｅｇｆアンチセンスオリゴヌクレオチド
CA2251945A1 (en) 1996-04-17 1997-10-23 Aronex Pharmaceuticals, Inc. Antisense inhibitors of vascular endothelial growth factor (vefg/vpf) expression
WO1998027425A1 (en) 1996-12-19 1998-06-25 Isis Pharmaceuticals, Inc. Large-scale purification of full length oligonucleotides by solid-liquid affinity extraction
JPH1142091A (ja) 1997-07-25 1999-02-16 Toagosei Co Ltd アンチセンス核酸化合物
AUPP249298A0 (en) * 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
WO1999063975A2 (en) 1998-06-10 1999-12-16 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH A method for stimulating the immune system
JP2002529421A (ja) 1998-11-06 2002-09-10 ビーエーエスエフ アクチェンゲゼルシャフト 血管過浸透性の阻害方法
EP1325121A2 (en) 2000-10-13 2003-07-09 Institut de Cardiologie de Montreal Antisense oligonucleotide directed toward mammalian vegf receptor genes and uses thereof
AU2002256359A1 (en) 2001-04-24 2002-11-05 Epigenesis Pharmaceuticals, Inc. Antisense and anti-inflammatory based compositions to treat respiratory disorders
WO2002085309A2 (en) 2001-04-24 2002-10-31 Epigenesis Pharmaceuticals, Inc. Composition, formulations & kits for treatment of respiratory & lung disease with anti-sense oligonucleotides & a bronchodilating agent
US7517864B2 (en) * 2001-05-18 2009-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
WO2003070910A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20050148530A1 (en) * 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
FR2832154B1 (fr) 2001-11-09 2007-03-16 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
EP1432724A4 (en) 2002-02-20 2006-02-01 Sirna Therapeutics Inc RNA inhibition mediated inhibition of MAP KINASE GENES
US7148342B2 (en) * 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
US20100113307A1 (en) 2002-11-14 2010-05-06 Dharmacon, Inc. siRNA targeting vascular endothelial growth factor (VEGF)
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
AU2003295600A1 (en) 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
US20040191818A1 (en) * 2003-02-26 2004-09-30 O'toole Margot Mary Compositions and methods for diagnosing and treating autoimmune diseases
JP4605799B2 (ja) * 2003-04-02 2011-01-05 ダーマコン， インコーポレイテッド Ｒｎａ干渉において使用するための修飾ポリヌクレオチド
JP2008167739A (ja) * 2006-06-14 2008-07-24 National Institute Of Advanced Industrial & Technology Ｒｎａ干渉効果が高い修飾型二本鎖ｒｎａ
AU2007299705B2 (en) * 2006-09-22 2012-09-06 Dharmacon, Inc. Duplex oligonucleotide complexes and methods for gene silencing by RNA interference
WO2008045576A2 (en) * 2006-10-12 2008-04-17 Yijia Liu Compositions and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases
WO2008109362A1 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting vegf gene expression and uses thereof
WO2009045356A2 (en) * 2007-09-28 2009-04-09 Yale University Microrna compositions in the treatment of vegf-mediated disorders
US8188060B2 (en) * 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
KR101397407B1 (ko) * 2008-03-05 2014-06-19 알닐람 파마슈티칼스 인코포레이티드 Ｅｇ5 및 ＶＥＧＦ 유전자의 발현을 억제하기 위한 조성물 및 방법
AU2009322279A1 (en) * 2008-12-04 2011-07-14 Opko Pharmaceuticals, Llc Compositions and methods for selective inhibition of pro-angiogenic VEGF isoforms

Also Published As

Publication number Publication date
WO2012015775A3 (en) 2012-08-09
AR082411A1 (es) 2012-12-05
ZA201300531B (en) 2014-03-26
RU2013102545A (ru) 2014-09-10
AU2011282902B2 (en) 2015-01-29
WO2012015775A2 (en) 2012-02-02
US9150862B2 (en) 2015-10-06
US8546349B2 (en) 2013-10-01
MX2013000986A (es) 2013-07-03
AU2011282902A1 (en) 2013-01-31
KR20130095737A (ko) 2013-08-28
PH12013500187A1 (en) 2013-04-08
JP2013539456A (ja) 2013-10-24
US20140031414A1 (en) 2014-01-30
EP2598639A2 (en) 2013-06-05
CL2013000237A1 (es) 2014-03-21
TW201219041A (en) 2012-05-16
EP2598639A4 (en) 2014-08-13
CA2804847A1 (en) 2012-02-02
CN103068981A (zh) 2013-04-24
BR112013001918A2 (pt) 2016-05-24
US20120029051A1 (en) 2012-02-02

Similar Documents

Publication Publication Date Title
UY33533A (es) siRNA DIRIGIDO AL VEGFA Y A MÉTODOS DE TRATAMIENTO IN VIVO
MX2013010557A (es) Anticuerpo del factor tisular humano y usos de este.
MX2010005018A (es) Tratamiento de complicaciones de nacimiento prematuro.
NZ701715A (en) Means and methods for treating dlbcl
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
NZ609223A (en) Vasoprotective and cardioprotective antidiabetic therapy
EA201201186A1 (ru) ИСПОЛЬЗОВАНИЕ ErbB3 ИНГИБИТОРОВ В ЛЕЧЕНИИ ТРИЖДЫ НЕГАТИВНОГО И БАЗАЛЬНО-ПОДОБНОГО ВИДОВ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
NZ602798A (en) Treatment of sarcoidosis using placental stem cells
EP2249861A4 (en) Treating neurodegenerative diseases with progranulin (pgrn)
MX2010003217A (es) Celulas angiogenicas de perfundido de placenta humana.
PH12012501037A1 (en) Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
EA201490509A1 (ru) Биосовместимый катетер
EA201101568A1 (ru) Лечение ex vivo иммунологических нарушений с помощью ингибиторов pkc-teta
TR201818927T4 (tr) Kataterlerde İyileştirme
MX354144B (es) Metodo, fabricacion y uso de productos medicos que liberan sustancia activa para mantener vasos sanguineos abiertos.
MX357749B (es) Tratamiento contra el dolor utilizando células madre placentarias.
BR112014017161A2 (pt) dispositivo de oclusão implantável, método de fazer um dispositivo de oclusão implantável, dispositivo para limitar o fluxo de fluido e método para ocluir um lúmen num tecido corporal
CL2012002326A1 (es) Uso de una combinación de por lo menos un agente quimioterapéutico y una cantidad efectiva de un anticuerpo anti-vegf (factor de crecimiento endotelial vascular), porque sirve para preparar un medicamento útil en el tratamiento de cáncer ovárico; y su kit para tratar el cáncer ovárico sin tratamiento anterior en una paciente humana.
CL2011002610A1 (es) Metodo de terapia complementaria que comprende la administracion a un paciente con cancer luego de la cirugia definitiva de un antagonista especifico del factor de crecimiento endotelial vascular (vegf) durante mas de un ano; y kit.
EP2608797A4 (en) BONE MARROW-OBTAINED CD271 CELLARS FOR HEART REPAIR
MX376241B (es) Uso de anticuerpos anti-il-1a en el tratamiento de enfermedades vasculares y sus complicaciones.
TR201109999A2 (tr) Trombositten zengin fibrin yapımı için tüp.
GEP201706716B (en) Optimised subcutaneous therapeutic agents
MX2010006650A (es) Materiales y metodos para el tratamiento de proliferacion vascular ocular patologica.
EA201390925A1 (ru) Производные санглиферина и способы их получения

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20200813